Serum HBsAg kinetics in relation to hepatitis flare during first 6 months of direct antiviral therapy
AASLD LiverLearning®. Jeng R. Nov 14, 2016; 144784
Topic: Treatment and Clinical Trials
Dr. Rachel Wen-Juei Jeng
Dr. Rachel Wen-Juei Jeng
Login now to access Regular content available to all registered users.

AASLD Members enjoy free LiverLearning® Premium Access. Registrants of The Liver Meeting® receive LiverLearning® Premium Access for one year from the first day of the meeting.

You may also access AASLD content "anytime, anywhere" with the FREE AASLD LiverLearning® App for iOS and Android.

Abstract
Discussion Forum (0)
Rate & Comment (0)
ABSTRACT FINAL ID: 1892

TITLE: Serum HBsAg kinetics in relation to hepatitis flare during first 6 months of direct antiviral therapy

SPONSORSHIP - THIS STUDY WAS SPONSORED BY: (IF THIS ABSTRACT WAS NOT SPONSORED PLEASE INDICATE):
nil

ABSTRACT BODY:
Background:
The decline of hepatitis B surface antigen (HBsAg) level during nucleos(t)ide analog (Nuc) therapy in chronic hepatitis B is usually slow and small. However, earlier study showed “rapid HBsAg decline” ≥0.5 log10 IU/mL by month 6 of entecavir therapy in over 50% of the patients with pretherapy alanine aminotransferase (ALT) > 5X upper limit of normal (ULN). Of note, “rapid HBsAg decline” was also observed in 7% of the patients with pretherapy ALT < 5X ULN.
Aim: To investigate who and why patients with pretherapy ALT <5X ULN showed “rapid HBsAg decline” during Nuc treatment
Patients and methods:
Patients with pretherapy ALT <5X ULN and HBsAg quantification at baseline, month 6 and 12 of Nuc tehrapy were included. “Significant ALT elevation” was defined as >10% increase above baseline level and >2X ULN during first 6 months of Nuc therapy. “Hepatitis flare” was defined as an event with abrupt ALT elevation to >5X ULN. Serum HBV DNA was measured using Cobas Amplicor HBV Monitor(Roche Diagnostics, Pleasanton, California; detection range 20-1.7*108IU/ml). HBsAg was measured using Roche Elecsys® II kit. (detection range 0.05-52000 IU/mL)
Results:
Among 263 patients meeting the inclusion criteria, 55 experienced transient “significant ALT elevation” [Group A], including 33 (12.6%) with peak ALT of 2-5X ULN [group A-1] and 22 (8.4%) > 5X ULN (hepatitis flare) [group A-2]. The remaining 208 patients showed no ”significant ALT elevation” [group B]. HBsAg decline at month 6 was significantly greater in group A than in group B (-0.364 vs -0.047 log10 IU/mL; P=0.000), greatest in group A-2 and smallest in group B-1 (-0.523 vs -0.025 log10 IU/mL; P=0.000). “Rapid HBsAg decline” by month 6 was documented in 38.2% of group A and 9.6% of group B patients (P=0.000), highest in group A-2 and lowest in group B-1 patients (50% vs 2.2%). Of the group B patients, those with a baseline ALT of 2-5X ULN (group B-2) showed greater HBsAg decline (-0.104 vs -0.025 log10 IU/mL, P=0.000) and more frequent rapid HBsAg decline (15.3% vs 2.2%; P=0.001) at month 6 of therapy than those with a baseline ALT of <2X ULN (group B-1).
Conclusion:
Hepatitis B flare (ALT>5X ULN) developed during Nuc therapy in 8.4% of the patients with prehterapy ALT<5XULN, and 50% of the patients developing hepatitis flare showed “rapid HBsAg decline” >-0.5 log10 IU/mL by moth 6 of Nuc therapy. Only 10% of the patients without ”significant ALT elevation” showed “rapid HBsAg decline” which occurred mainly in those with pretherapy ALT of 2-5X ULN. These findings suggest the importance of immune factor(s) for HBsAg decline during Nuc therapy.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings